Curanex Pharmaceuticals Inc CURX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 652.82% | 488.18% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2,821.62% | 1,995.20% | -- | -- | -- |
| Operating Income | -2,821.62% | -1,995.20% | -- | -- | -- |
| Income Before Tax | -2,306.53% | -1,627.79% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2,306.53% | -1,627.79% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,306.53% | -1,627.79% | -- | -- | -- |
| EBIT | -2,821.62% | -1,995.20% | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -647.82% | -294.31% | -- | -- | -- |
| Normalized Basic EPS | -676.70% | -305.72% | -- | -- | -- |
| EPS Diluted | -647.82% | -294.31% | -- | -- | -- |
| Normalized Diluted EPS | -676.70% | -305.72% | -- | -- | -- |
| Average Basic Shares Outstanding | 21.85% | 53.56% | -- | -- | -- |
| Average Diluted Shares Outstanding | 21.85% | 53.56% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |